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Streptococcus suis, a Gram-positive pathogen, is widely recognized as an important
agent of swine infection, and it is also known to cause a variety of zoonoses, such
as meningitis, polyarthritis and pneumonia. Suilysin (SLY), an extracellular pore-forming
toxin that belongs to the cholesterol-dependent cytolysin family, is an essential virulence
factor of S. suis capsular type 2 (SS2). Here, we found that morin hydrate (morin),
a natural flavonoid that lacks anti-SS2 activity, inhibits the hemolytic activity of SLY,
protects J774 cells from SS2-induced injury and protects mice from SS2 infection.
Further, by molecular modeling and mutational analysis, we found that morin binds to
the “stem” domain 2 in SLY and hinders its transformation from the monomer form to
the oligomer form, which causes the loss of SLY activity. Our study demonstrates that
morin hinders the cell lysis activity of SLY through a novel mechanism of interrupting
the heptamer formation. These findings may lead to the development of promising
therapeutic candidates for the treatment of SS2 infections.
Keywords: Streptococcus suis, suilysin, morin, anti-infective, molecular modeling
INTRODUCTION
Streptococcus suis (S. suis) is a Gram-positive coccus and emerging zoonotic agent whose global
spread could cause a variety of life-threatening infections, including, but not limited to, sepsis,
arthritis, meningitis, encephalitis, endocarditis and pneumonia in swine and humans (Lun et al.,
2007; Goyette-Desjardins et al., 2014). So far, there are 35 (1–34 and 1/2) official serotypes that
have been identified based on capsular antigens (Gottschalk et al., 2007). Serotype 2 is the most
frequently isolated from clinically diseased piglets (Yang et al., 2006; Aspiroz et al., 2009; Okura
et al., 2016) and is responsible for significant economic losses to the porcine industry worldwide,
causing more than $300 million in losses in the US alone (Heidt et al., 2005). Since 1968 when the
first human case of S. suis infection was reported in Denmark, more than 1600 human cases have
been documented worldwide (Hedegaard et al., 2013). Most of these infections occur in people
who work with pigs or in those who are in close contact with raw pork products in Southeast Asia,
where there is a high density of pigs (Wertheim et al., 2009). In China, two large outbreaks of
S. suis infection were recorded in 1998 and 2005, which caused substantial economic losses to the
pig industry and many human deaths, representing a significant public health concern (Ye et al.,
2006; Yu et al., 2006).
To successfully establish an infection, S. suis must overcome epithelial barriers, evade immune
attack, survive in the bloodstream and invade various organs, deliberately causing exaggerated
local inflammation. Each of these steps is mediated by multiple stages of virulence factors
synthesized by the bacterium (Fittipaldi et al., 2012). Therefore, the targeting of such virulence
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determinants may be a promising therapeutic strategy for the
treatment of S. suis infections. Suilysin (SLY, encoded by the gene
sly), a 54 kDa extracellular pore-forming protein that belongs
to the family of cholesterol-dependent cytolysin, is a virulence-
associated factor secreted by most virulent S. suis strains and
is regarded as a virulence marker of S. suis (Tenenbaum et al.,
2016). Over the past 20 years, SLY has been shown to lyse
different cell types, which would affect complement activity,
increase the blood-brain barrier and/or blood-cerebrospinal fluid
barrier permeability, induce the inflammatory reactions of host
and facilitate bacterial infection (Du et al., 2013; Leung et al.,
2014). Staats’s group reported that 5 of 19 strains of capsular
type 2 S. suis are SLY positive, which are highly virulent in
pigs based on mortality, morbidity and pathology. While the
remaining 14 SLY-negative strains are lower virulent or avirulent
(Staats et al., 1998). In a recent study, Takeuchi et al. generated a
sly-knockout strain and identified SLY as an important virulence
factor in a mouse model of S. suis infection (Takeuchi et al.,
2014). Approximately 90% of mice inoculated with S. suis ST1,
a strain that produces high levels of SLY, were dead within 10
days. In contrast, similar infections with sly-knockout ST1 or the
S. suis ST104 strain, a natural isolate that produces only low levels
of SLY, failed to cause mortality within the same experimental
timeframe. Furthermore, their study illustrates that the S. suis
strain with higher-level production of SLY more frequently causes
meningitis. In summary, SLY was confirmed to contribute to
higher bacterial density, enhanced inflammation in the brain,
increased mortality in mice and the pathogenesis of meningitis
in humans (Takeuchi et al., 2014). Therefore, SLY may represent
a novel therapeutic target for the treatment of S. suis infection.
Morin hydrate (morin), a yellow natural bioflavonoid
compound found in many members of the Moraceae
family and various fruits and vegetables, has been shown
to possess multiple pharmacological effects, including anti-
inflammatory, anti-proliferative and anti-oxidant activities
(Krol et al., 2002; Fang et al., 2005; Green et al., 2012;
Lee et al., 2016). Additionally, several recent studies have
shown that morin can significantly attenuate the virulence of
pathogenic bacteria (Huang et al., 2014; Wang et al., 2015;
Sivaranjani et al., 2016). However, to our knowledge, the
influence of morin on SLY and S. suis virulence has not been
reported previously. In this study, morin was identified as
an effective SLY inhibitor by a hemolysis assay. Furthermore,
the virulence of S. suis was significantly attenuated in the
presence of morin. These findings suggest that morin could be
a promising therapeutic candidate for the treatment of S. suis
infection.
MATERIALS AND METHODS
Bacterial Strain, Culture Conditions, and
Morin Preparation
The bacterial strain ZY05719 (highly virulent S. suis serotype 2)
used in this study was a gift kindly provided by Professor Hongjie
Fan (Key Lab of Animal Bacteriology, Ministry of Agriculture,
Nanjing Agricultural University, Nanjing, China). SS2 strain
ZY05719 was cultured in Todd-Hewitt broth (THB; Qingdao
Hope Biol-Technology Co., Ltd, Qingdao, China) at 37◦C. Morin
was commercially obtained from Chengdu Herbpurify CO.,
LTD (Chengdu, China) and was dissolved in dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St Louis, MO, USA) to make a stock
solution (40.96 mg/ml).
Production of Recombinant SLY Protein
and Anti-SLY Rabbit Serum
Streptococcus suis sly cDNA was subcloned into pET-28a(+)
vector (Novagen, Madison, WI, USA) with BamHI and NdeI
restriction enzyme cutting sites to construct the prokaryotic
expression plasmid pET-28a(+)-SLY. The recombinant
plasmid encoding the histidine-tagged SLY protein (rSLY) was
transformed in E. coli BL21. Recombinant protein expression
was induced by the addition of 0.2 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) at 16◦C for 16 h. The supernatant
of bacterial cell lysates was loaded onto a Ni-NTA column to
purify the resultant rSLY protein.
The expression vectors for the SLY-Tyr54Ala, SLY-Gln107Ala
and SLY-Asp111Ala mutants were constructed using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) based on pET-28a(+)-SLY and were verified by DNA
sequencing. The expression and purification of these mutants was
performed as described above for wildtype SLY (WT-SLY). The
primers used in this study for the construction of pET-28a(+)-
SLY and its derivatives are listed in Table 1.
Approximately 3 mg rSLY protein was sent to Tianjin Sungene
Biotech Co., Ltd. (Tianjin, China) for the production of anti-
SLY rabbit serum, which was confirmed by western blot to detect
recombinant SLY protein and secreted SLY in bacterial culture
supernatants.
Anti-bacterial Activity of Morin against
S. suis
SS2 was cultured in THB and diluted at a density of 5 × 105
CFUs/ml. The minimal inhibitory concentration (MIC) of morin
for SS2 was measured by a serial dilution method, according to
the procedures of the CLSI guideline M31-A2 (CLSI, 2002). Lag-
phase bacterial cultures were divided into 10 mL aliquots, and
morin was added to yield the desired final concentrations of 0, 4,
8, 16, and 32 µg/mL. To determine the growth kinetics, bacterial
densities were monitored every 30 min at an OD of 600 nm
for 6 h.
Hemolysis Assay
Streptococcus suis strain SS2 from an overnight culture was
transferred (1:50) to THB with various concentrations of
morin (0, 4, 8, 16, and 32 µg/mL) and further cultured to
the stationary phase (OD600 = 2.5). Then, the bacteria were
pelleted by centrifugation (10,000 rpm, 1 min) to obtain culture
supernatants. Defibrinated rabbit blood was suspended in PBS to
2.5% vol at a final volume of 1 mL and was incubated with 100 µL
culture supernatant at 37◦C for 30 min in parallel with controls
containing either no culture supernatants (negative control)
or 2.5% vol Triton X-100 (positive control). After incubation,
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TABLE 1 | The binding free energy (kcal/mol) of WT-morin, Tyr54Ala-morin,
Gln107Ala-morin, and Asp111Ala-morin based on a computational
method and the values of the binding constants (KA) based on
fluorescence spectroscopy quenching.
WT-SLY Tyr54Ala Gln107Ala Asp111Ala
Computational Method –12.7 ± 1.9 –8.3 ± 1.7 –7.1 ± 1.3 –6.9 ± 1.1
KA (1 × 104) L·mol−1 7.2 ± 1.4 5.1 ± 1.5 4.9 ± 1.2 4.8 ± 1.2
the reaction system was centrifuged (10,000 rpm, 1 min), and
the optical density at 543 nm (OD543) of the supernatant for
each sample was determined by ultraviolet spectrophotometry as
previously described (Wang et al., 2015).
The effect of morin on hemolysis induced by rSLY or its
derivatives was measured by incubating 100 µL purified proteins
(100 ng/mL) with the indicated concentrations of morin in 1 mL
PBS for 30 min at 37◦C prior to the addition of 25µL defibrinated
rabbit blood. Cell lysis was determined as described above.
Western Blot Assay
A total of 20 µL culture supernatants (as described above)
were mixed with Laemmli SDS sample buffer, boiled for 5 min
and separated by 12% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). The protein was transferred to
polyvinylidene difluoride membranes (PVDF, Bio-Rad, Hercules,
CA, USA) and SLY was visualized by primary anti-SLY rabbit
serum diluted 1:2000 and secondary horseradish peroxidase-
conjugated anti-rabbit antiserum (Sigma–Aldrich) diluted 1:4000
with Amersham ECL Western blotting detection reagents (GE
Healthcare, Buckinghamshire, UK), as described previously
(Wang et al., 2015).
Cell Culture and Infection
Mouse J774 macrophage-like cells were cultured at 37◦C in a
5% CO2 atmosphere in complete medium (Dulbecco modified
Eagle medium (DMEM, Invitrogen) supplemented with 10%
fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL
streptomycin). The cells were seeded at a density of 2 × 104
cells per well in 96-well plates overnight and were subsequently
infected with SS2 at the mid-log phase (OD600 = 0.8–1) of
bacterial culture and resuspended in FBS-free DMEM medium
at a multiplicity of infection (MOI) of 10 with various
concentrations of morin for 5 h. Cells treated with 2.5% vol
Triton X-100 or DMEM served as the positive and negative
controls, respectively. The supernatants were harvested from
each well by centrifugation (1,000 rpm, 10 min), and the presence
of LDH released into supernatants was measured using the
Cytotoxicity Detection Kit (LDH; Roche, Basel, Switzerland)
according to the manufacturer’s instructions. Microscopic images
of stained cells were further obtained under a confocal laser
scanning microscope (Nikon, Tokyo, Japan) using live/dead
(green/red) reagent (Invitrogen).
For the transwell experiment, 1 mL J774 cells (5 × 104
cells/mL) in complete medium were plated in the upper chamber
of 24-well transwell plates (Costar, 3.0 µm in pore size) for 3 days,
and 500 µL complete medium without antibiotics was added
in the lower chamber. At days 4, 6, and 7, the concentrations
of FBS in the upper chamber were changed to 5, 1, and 0%,
respectively. Upon reaching confluence after 8 days, the cells in
each chamber were infected with 200 µL SS2 (1 × 108 CFU/mL)
at the mid-log phase (OD600 = 0.8–1) of bacterial culture and
resuspended in FBS-free DMEM medium in the presence of
32 µg/mL morin for 15 min. The number of bacteria in the lower
chamber was calculated by titrating on THB plates to determine
the penetration ability of SS2 through J774 in the presence or
absence of morin. The percentage of penetration = 100 × lower
chamber CFUs/ upper chamber added CFUs.
Mouse Model of S. suis Infection
Eight-week-old female C57BL/6J mice were purchased from the
Experimental Animal Center of Jilin University (Changchun,
China). The animal experiments were reviewed and approved by
the Animal Care and Use Committee of Jilin University.
Overnight cultures of SS2 were transferred into THB (diluted
1:500) and grown at 37◦C to mid-log phase (OD600= 0.8-1). Cells
were centrifuged (3,000 rpm, 10 min), washed once with PBS and
suspended in PBS to a final concentration of 1 × 109 CFU/mL.
Mice were inoculated intravenously with 100 µL of the bacterial
suspension. Two hours after inoculation, morin was administered
subcutaneously at 100 mg/kg and at the same dosage at 8-hour
intervals. Infected mice administered with DMSO served as the
control group. The infected mice (30 per group) were observed
for survival analysis for up to 4 days.
Molecular Modeling
The structure of SLY was taken from the X-ray crystal structure in
the Protein Data Bank (PDB) with PDB codes of 3HVN. The free
protein obtained from the PDB (3HVN) was first equilibrated by
a 100 ns molecular simulation on the solute, which was used for
the molecular docking with morin. Then, the geometry of morin
was optimized at the B3LYP/6-31G∗ level by the Gaussian 03
program. Subsequently, the standard docking procedure for SLY
with morin was performed by using AutoDock4. The detailed
process is reported in our previous paper (Dong et al., 2013;
Wang et al., 2015).
In this study, complex systems were investigated by MD
simulations using the Gromacs 4.5.2 software package based
on the Amber99sb force field and TIP3P water model. The
electrostatic term was described by using the particle mesh Ewald
algorithm method, and all bond lengths were constrained by
the LINCS algorithm. The initial velocity was obtained from
a Maxwellian distribution. The desired initial temperature was
300 K. The density of the system was adjusted by NPT condition
(P0 = 1 bar, coupling time τp = 0.5 ps). The protein and
non-protein systems were coupled separately to the temperature
bath. The antechamber programs and AM1-BCC partial atomic
charges from the Amber 10 software were used to estimate
morin. In this work, the binding free energies between SLY
and morin were calculated by the Molecular Mechanis/Poisson-
Boltzman Surface Area (MM-PBSA) method supplied with the
Amber 10 package. Then, the interaction between inhibitors and
each residue in the binding site of SLY was analyzed using the
MM-PBSA decomposition process.
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To verify the result of MD simulations, the interactions
between morin and WT-SLY, SLY-Tyr54Ala, SLY-Gln107Ala, and
SLY-Asp111Ala were investigated by fluorescence quenching.
The proteins were used as the fluorophore and morin was used
as the quencher. Commonly, fluorescence quenching can be
described by the following Scatchard equation: r/Df = nK–rK,
where r is the ligand amount of substance per mole of protein
binding (r ≈ 1F/F0), Df is the free concentration of morin, K
is the binding constant and n is the number of binding sites. In
this system, due to the morin concentration being far greater
than the concentration of protein; the Df is replaced by the
total morin concentration. According to experimental results, the
linear fitting plots of r/Df vs r between morin and WT-SLY, SLY-
Tyr54Ala, SLY-Gln107Ala, or SLY-Asp111Ala could be made. The
values of K and n could be obtained based on the plots.
Statistical Analysis
All experimental data (n ≥ 3) are expressed as the mean ± SD.
GraphPad Prism 5.0 was used for statistical analysis using
Student’s t-test. Significance levels of P < 0.05 and P < 0.01 are
indicated in the figures.
RESULTS
Morin Inhibits SLY Hemolytic Activity
The hemolytic activity of culture supernatants from the
stationary phase of SS2 was measured by a hemolysis
assay in the presence of various concentrations of morin
(Figures 1A,B). As shown in Figure 1B, the SLY protein
secreted by S. suis at the stationary phase could sufficiently
induce hemolysis, as 85.38% of red blood cells were lysed by
the control sample in the absence of morin. However, upon
co-culture with morin, the hemolytic activities of bacterial
supernatants were significantly decreased in a concentration-
dependent manner (Figure 1B). This finding suggests that
such inhibition was due to a suppression of SLY activity by
morin or a direct neutralization of SLY-mediated hemolysis by
morin.
Western blot analysis was performed to detect the level of
secreted SLY protein in culture supernatants and, interestingly,
no visible difference was observed between control and morin-
treated samples (Figure 1C). Additionally, the MIC of morin
against SS2 was greater than 1,024 µg/mL, and morin had
no influence on SS2 growth at the concentrations required
to inhibit the hemolytic activity of culture supernatants
(Figure 1D). These data indicate that morin has effectively no
antimicrobial activity against SS2. Furthermore, the effect of
morin on purified recombinant SLY (rSLY)-mediated hemolysis
was evaluated, and, consistent with the results described above,
the addition of morin significantly reduced the hemolytic
activity of rSLY (Figure 1E). Taken together, these findings
reveal that the inhibition of the hemolytic activity of bacterial
culture supernatants by morin was not due to a decreased
production of SLY in the supernatants but may be due
to the direct binding of morin to SLY to neutralize SLY
activity.
Morin Alleviates SS2-Mediated Cell
Injury
A live/dead (green/red) assay and LDH assay were further
employed to verify the potential protection of morin against SS2
in vitro. 37.73% cells were dead in the sample infected with SS2,
while fewer dead cells were found in the morin-treated samples
(Figures 2A,B). The release of LDH by J774 was assessed to
quantify such protection. In agreement with the above results,
morin treatment significantly alleviated SS2-mediated cell injury
in a concentration-dependent manner (Figure 2B). Additionally,
almost no cell injury was observed in the cells treated with only
morin, suggesting that this compound had no cytotoxicity in J774
cells (Figure 2A).
Suilysin has been proven to play a crucial role in the process
of SS2 traversal across the epithelial barrier (Du et al., 2013;
Leung et al., 2014). To determine the effect of morin on the
penetrability of pathogenic SS2, J774 monolayers were used to
model the epithelial barrier by plating into transwell permeable
supports, as described above. We found that morin-treated SS2
failed to pass though monolayer cells while the control group
allowed for pathogenic traversal (Figure 2C), indicating that
morin inhibits SLY function in a similar manner to cholesterol,
which is consistent with previous findings (Charland et al., 2000).
Taken together, our results establish that treatment with morin
significantly inhibits the penetration of SS2 through the epithelial
barrier and SS2-induced cell injury.
Morin Protects Mice from SS2 Infection
To examine whether the protection of morin against S. suis
virulence was also observed in vivo, the survival rate of SS2-
infected mice treated with morin was compared to untreated
infected mice. Importantly, the survival rate of infected mice was
significantly different between the morin-treated and untreated
groups. Consistent with previous findings, all infected mice were
dead at 96 h post-infection (Figure 3); however, this mortality
rate was decreased to 56.67% (Figure 3). In summary, our results
suggest that morin treatment leads to a substantial inhibition on
SS2-induced death in infected mice.
Determination of the Molecular
Mechanism Underlying Morin Inhibition
of SLY Activity
Over the 100-ns of MD simulation, it was found that morin
localized to domain 2 of SLY, as shown in Figure 4A. From
the binding mode of SLY-morin, it was shown that there are
three strong hydrogen bonds between morin and Thr49, Tyr54,
and Gln107. Moreover, Asn50 and Asp111 also have a strong
hydrophobic interaction with morin (Figure 4A). The number of
H-bonds between morin and SLY during the 200-ns simulation
are plotted in Figure 4B, which is consistent with the above
results.
It is widely accepted that the flexibility of the residue can be
revealed by the calculation of the root mean square fluctuation
(RMSF) of the protein. As such, the RMSF of these residues
around the binding sites of the SLY complex and free SLY
are shown in Figure 4C. Interestingly, our analysis reveals that
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FIGURE 1 | Inhibition of SLY-induced hemolysis by morin. (A) The chemical structure of morin. (B) The inhibitor effect of morin on the hemolytic activity of
bacterial culture supernatants after co-culture with SS2. SS2 was co-cultured with morin, and the hemolytic activity of culture supernatants was determined using a
hemolysis assay. The percent hemolysis of each sample was calculated by comparison with the control sample. (C) Western blot analysis of the SLY level in the
culture supernatants. (D) The growth of SS2 in the presence of the indicated morin concentrations. SS2 was co-cultured with various concentrations of morin, and
the growth kinetics were determined by measuring the OD600 of each sample every 30 min. (E) Inhibition of purified rSLY activity by morin. Following an incubation
with the indicated concentrations of morin, the hemolytic activity of rSLY was examined by hemolysis assay. ∗ indicates P < 0.05, and ∗∗ indicates P < 0.01
compared with the morin-free sample (two-tailed Student’s t-test).
the flexibilities in the SLY binding sites are different in the
presence and absence of morin, which suggests that the residues
in the binding sites of the SLY complex are more rigid as a
result of ligand binding. In Figure 4C, the residues (50–60 and
100–120) in the protein-morin binding sites show a small degree
of flexibility with RMSF of less than 0.1 nm when compared with
free protein, indicating that these residues seem to be more rigid
as a result of ligand binding.
To obtain detailed information of the residues in the SLY-
morin binding region and their contribution to the whole system,
the ligand-residue interaction decomposition was calculated for
the complex system by an MM-PBSA method. As shown in
Figure 4D, Thr49, Gln107, and Asp111 provide appreciable
electrostatic contributions, with1Eele values of∼–1.43,∼–1.28,
and ∼–10.34 kcal/mol, respectively. Moreover, Asn50, Tyr54,
and Gln107 have the strongest attraction interaction, with van
der Waals values of ∼–3.10, ∼–2.08, and ∼–2.65 kcal/mol,
respectively. With the exception of Asp111, the majority of
the decomposed energy interactions originated from Van der
Waals interactions, while electrostatic contributions appeared
to be a minor influence on these key residues. Based on the
above results, we conclude that the amino acid residues of
Thr49, Asn50, Tyr54, Gln107, and Asp111 may be important
for morin binding. Hemolysis assay was further performed
to detect the inhibitory activity of morin on hemolysis
induced by rSLY and its derivatives. Three SLY mutants
(Tyr54Ala, Gln107Ala, and Asp111Ala) remain active for lying
defibrinated rabbit blood (Figure 4E), however, the inhibition
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FIGURE 2 | Attenuation of SS2-induced cell injury and epithelial barrier
penetration by morin. (A) J774 cells were infected with SS2 in the presence
or absence of morin, stained with live (green)/dead (red) agent and captured
using a confocal laser scanning microscope. (B) The LDH level in the
co-culture of SS2 and J774 cells treated with increasing concentrations of
morin was determined using a Cytotoxicity Detection Kit (LDH) to quantify
SS2-induced cell injury. Relative LDH release of each sample = (OD of tested
group – OD of negative group)/(OD of positive group – OD of negative
group) × 100%. (C) J774 cells were plated and cultured onto an epithelial
barrier and then infected with SS2. The penetration rate of SS2 was examined
by a CFU assay. ∗ indicates P < 0.05, and ∗∗ indicates P < 0.01 compared
with the morin-free sample (two-tailed Student’s t-test).
of morin on these mutations was alleviative than WT-SLY
(Figure 4E).
To confirm this hypothesis, the total binding free energy for
the SLY-morin complex and their detailed energy contributions
FIGURE 3 | Morin treatment significantly inhibits the mortality of
infected mice. Infected mice were treated with morin or DMSO as a negative
control, and the mortality of infected mice was statistically analyzed for 96 h
using the Kaplan–Meier method.
(calculated according to the MM-PBSA approach) are
summarized in Table 1. According to the theoretical results, the
binding free energy (1Gbind) of the interaction between morin
and protein is greater for WT-SLY than mutant SLY, indicating
that WT-SLY has the strongest ability to bind with morin. By
fluorescence spectroscopy quenching, we measured the binding
constants (KA) and the number of binding sites between morin
and the three mutants, and the results of this analysis were
highly consistent with those obtained by computational biology
methods (Table 1). These findings indicate that the information
generated by the molecular modeling of the SLY-morin complex
is reliable.
To explore the mechanism of SLY inhibition by morin, a
principal component analysis (PCA) was performed on the MD
trajectory of free SLY and the SLY-morin complex to identify
the most significant motions of the protein. The first component
(PC1) of free SLY is composed of several motions (Figure 5A):
as a rigid body, there is an extended motion to the entire
conformation of the protein, particularly to the “stem” domain
2 (represented by the dotted line in Figure 5A). This motion is
sufficiently large to meet (but not exceed) the requirements for
the conformational transition of SLY from its monomer form to
an oligomer. The second principal component (PC2) primarily
corresponds to the slight vibration of the protein backbone, as
shown in Figure 5B. The PC1 of the complex is composed of
several motions, similar to that of the free protein, with the
exception of the motion in domain 2 (represented by the dotted
line in Figure 5C). The second principal component (PC2) was
shown in Figure 5D. As shown in Figure 5C, the motion of
domain 2 is clearly weaker than that of free SLY. It should be
noted that domain 2 is also the binding site of morin, based
on previous data. Therefore, it is confirmed that the motion of
domain 2 is restricted by the binding of morin. According to
previous reports, the toxin protein of the highly conserved CDC
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FIGURE 4 | The binding mode of morin with SLY based on the MD simulation. (A) The 3D structure and residues of the binding site in the SLY-morin complex;
(B) RMSF of the residue positions over the 200-ns simulations with respect to their initial position in SLY as a free protein and in complex; (C) The number of
hydrogen bonds between morin and SLY during the MD simulation; (D) Decomposition of the binding energy on a per-residue basis in the binding sites of the
SLY-morin complex; (E) The effect of morin on the hemolylsis induced by SLY and its derivatives, Tyr54Ala, Gln107Ala, and Asp111. ∗ indicates P < 0.05, and
∗∗ indicates P < 0.01 compared with the morin-free sample (two-tailed Student’s t-test).
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FIGURE 5 | Collective motions obtained by principal component analysis on the simulation trajectory. (A) and (B) Motions corresponding to PC1 and PC2
of the free SLY. (C,D) Motions corresponding to PC1 and PC2 of the SLY-morin complex.
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FIGURE 6 | Illustration depicting the mechanism underlying morin-mediated SLY inhibition. (A) During the transition from monomer to oligomer, many
aspects of the conformational changes have been directly observed, including the buckling of domain 2; (B) Binding to morin blocks the conformational change of
domain 2 from the monomeric to the oligomeric form, leading to the loss SLY lytic activity.
family can form the largest transmembrane β barrels. During
pore assembly, many aspects of pore formation have been directly
observed, including the buckling of domain 2. In this work, the
conformational change of domain 2 was clearly blocked upon
morin binding, inhibiting the formation of oligomers (Figure 6)
and causing the hemolytic activity of SLY to be lost.
DISCUSSION
To date, the ongoing exploration of antibiotics lags behind
the apparent ceaseless emergence of antibiotic-resistant bacteria
(Escaich, 2008). The irrational overuse of antibiotics in humans
and animals drives microbial mutagenesis and subsequent
resistance (Marra, 2006). Thus, the development of novel
strategies to fight antibiotic resistance and bacterial infection has
gradually evolved into an inevitable demand. The targeting of
virulence factors is an innovative strategy that exerts no selective
pressure on pathogen survival but instead lessens bacterial
pathogenicity (Dobrindt and Hacker, 2008; Rasko and Sperandio,
2010). Because SLY is important for the virulence of SS2, the
suppression of SLY is a potential approach that may decrease
SS2 virulence and reduce infectious symptoms without affecting
bacterial viability.
In this study, morin was identified to be an efficient
inhibitor of SLY by attenuating the hemolytic activity of SLY
and was verified to have no observed antibacterial activity
against SS2. Although the negligible antibacterial activity of
morin allows bacteria to reproduce in an unrestrained setting,
this compound can limit SS2 pathogenicity. In our in vitro
co-culture system, morin treatment significantly alleviated
SS2-induced cell injury and epithelial barrier penetration
according to a cytotoxicity assay and transwell experiment in
cell models. In vivo experiments showed that treatment with
morin also reduced death rates in C57BL/6J mice infected with
the aggressive SS2. The effect of morin on SS2 virulence may
be related to its anti-SLY activity. Thus, the inhibition of SLY
activity by morin decreases the severity of infections caused by
SS2 strains.
In this work, a standard molecular dynamics simulation
for the SLY-morin complex was performed. On the basis of
the MD simulation and the binding free energy calculations,
we found that morin could bind to the domain 2 of SLY by
forming strong contacts with residues Thr49, Tyr54, Gln107,
Asn50 and Asp111. These results were confirmed by ligand-
residue interaction decomposition using the MM-PBSA method,
residue point mutations, and a fluorescence-quenching assay.
To further explore the mechanism underlying SLY inhibition by
morin, a principal component analysis (PCA) was performed
on the MD trajectory of the free SLY and SLY-morin complex
to identify the most significant motions of the protein. Based
on our analysis of dynamic trajectory, we can predict that the
motion of domain 2 is restricted by the binding of morin
which blocks the conformational change of domain 2 from the
monomeric to oligomeric form to inhibit the lytic activity of SLY.
In addition, the declined sensibility of morin on hemolysis of SLY
mutations futher indicated that Tyr54, Gln107, and Asp111 are
three important amino acid residues for the engagement of morin
with SLY.
Morin is a flavonoid constituent extracted from Chinese herbs
and was reported to exhibit many biotic activities, such as anti-
inflammation and inhibition of the catalyzation of S. aureus
SrtA (Fang et al., 2005; Kang et al., 2006) In our previous
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study, morin treatment reduced the hemolytic activity of
S. aureus α-hemolysin (Wang et al., 2015). LLO and SLY
both belong to the cholesterol-dependent cytolysin family
(Heuck et al., 2010), suggesting that morin may inhibit
the activity of all CDC family members and other Gram
positive bacteria that secrete pore-forming toxins. In summary,
morin represents an alternative for the treatment of SS2
infections. Further research into morin may provide a new
therapeutic approach for antibiotic-resistant Gram positive
bacterial diseases.
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